Download MendeleyA Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential.
Wang, J., Bardelli, M., Espinosa, D.A., Pedotti, M., Ng, T.S., Bianchi, S., Simonelli, L., Lim, E.X.Y., Foglierini, M., Zatta, F., Jaconi, S., Beltramello, M., Cameroni, E., Fibriansah, G., Shi, J., Barca, T., Pagani, I., Rubio, A., Broccoli, V., Vicenzi, E., Graham, V., Pullan, S., Dowall, S., Hewson, R., Jurt, S., Zerbe, O., Stettler, K., Lanzavecchia, A., Sallusto, F., Cavalli, A., Harris, E., Lok, S.M., Varani, L., Corti, D.(2017) Cell 171: 229-241.e15
- PubMed: 28938115
- DOI: https://doi.org/10.1016/j.cell.2017.09.002
- Primary Citation of Related Structures:
5OMZ, 5Y0A - PubMed Abstract:
Zika virus (ZIKV), a mosquito-borne flavivirus, causes devastating congenital birth defects. We isolated a human monoclonal antibody (mAb), ZKA190, that potently cross-neutralizes multi-lineage ZIKV strains. ZKA190 is highly effective in vivo in preventing morbidity and mortality of ZIKV-infected mice. NMR and cryo-electron microscopy show its binding to an exposed epitope on DIII of the E protein. ZKA190 Fab binds all 180 E protein copies, altering the virus quaternary arrangement and surface curvature. However, ZIKV escape mutants emerged in vitro and in vivo in the presence of ZKA190, as well as of other neutralizing mAbs. To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a second mAb specific for DII of E protein. In addition to retaining high in vitro and in vivo potencies, FIT-1 robustly prevented viral escape, warranting its development as a ZIKV immunotherapy.
Organizational Affiliation:
Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; Centre for BioImaging Sciences, National University of Singapore, Singapore 117557, Singapore.
